Steven Cohen Larimar Therapeutics, Inc. Transaction History

Point72 Asset Management, L.P.

$36 Billion
Q2 2024

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 603,581 shares of LRMR stock, worth $3.8 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

603,581

Previous 603,581 -0.0%

Holding current value

$3.8 Million

Previous $4.38 Million -0.0%

% of portfolio

0.01%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$6.33 - $9.89 $1.05 Million - $1.63 Million	165,181 Added 37.68%	603,581 $4.38 Million
Q1 2024 May 15, 2024	SELL	$4.2 - $13.28 $50,400 - $159,360	-12,000 Reduced 2.66%	438,400 $3.33 Million
Q4 2023 Feb 14, 2024	SELL	$2.35 - $4.71 $10,810 - $21,666	-4,600 Reduced 1.01%	450,400 $2.05 Million
Q3 2023 Nov 14, 2023	SELL	$3.08 - $4.49 $1.18 Million - $1.72 Million	-384,000 Reduced 45.77%	455,000 $1.8 Million
Q2 2023 Aug 14, 2023	BUY	$3.13 - $5.27 $1.2 Million - $2.02 Million	384,000 Added 84.4%	839,000 $2.63 Million
Q1 2023 May 15, 2023	SELL	$4.0 - $6.68 $80,000 - $133,600	-20,000 Reduced 4.21%	455,000 $2.06 Million
Q3 2022 Nov 14, 2022	BUY	$1.53 - $3.64 $726,750 - $1.73 Million	475,000 New	475,000 $1.52 Million
Q1 2022 May 16, 2022	SELL	$3.65 - $10.84 $718,670 - $2.13 Million	-196,896 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$9.61 - $15.11 $939,242 - $1.48 Million	97,736 Added 98.56%	196,896 $2.27 Million
Q2 2021 Aug 16, 2021	BUY	$8.0 - $15.2 $655,200 - $1.24 Million	81,900 Added 474.51%	99,160 $974,000
Q2 2020 Aug 14, 2020	BUY	$0.72 - $16.76 $12,427 - $289,277	17,260 New	17,260 $222,000

Others Institutions Holding LRMR

# of Institutions

111

Shares Held

68M

Call Options Held

290K

Put Options Held

38.9K

View Full List

About Larimar Therapeutics, Inc.

Ticker LRMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,269,200
Market Cap $273M
Description
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...

More about LRMR

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account